Welcome to Abbott's third quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by ...

Abbott Laboratories (NYSE:ABT) increased its full-year earnings guidance on Tuesday after its financials for Q3 2024 exceeded ...

Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...

Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...

Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...

With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...

ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna ...

On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street ...

Abbott has raised the midpoint of its full-year income guidance as the group was bolstered by solid sales of medical devices ...

Abbott Laboratories' MedTech portfolio currently contributes around 45% of total sales of about $42 billion.